Picture loading failed.

Anti-PDCD1 therapeutic antibody (Pre-made Dostarlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-154-1mg 1mg 3090
GMP-Bios-ab-154-10mg 10mg 21890
GMP-Bios-ab-154-100mg 100mg 148000
GMP-Bios-ab-154-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1 therapeutic antibody (Pre-made Dostarlimab biosimilar,Whole mAb)
INN Name Dostarlimab
TargetPDCD1/PD-1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO
Conditions Approvedna
Conditions ActiveFallopian tube cancer;Ovarian cancer;Peritoneal cancer;Endometrial cancer;Non-small cell lung cancer;Solid tumours;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer
Conditions Discontinuedna
Development Techna